Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Nature reviews. Clinical oncology - 1 Nov 2016

Bianchini Giampaolo, Balko Justin M, Mayer Ingrid A, Sanders Melinda E, Gianni Luca

Abstract excerpt

Chemotherapy is the primary established systemic treatment for patients with triple-negative breast cancer (TNBC) in both the early and advanced-stages of the disease. The lack of targeted therapies and the poor prognosis of patients with TNBC have fostered a major effort to discover actionable molecular targets to treat patients with these tumours. Massively parallel sequencing and other 'omics' technologies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Androgen Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune System

Share to Immunotherapy

Share to Neoplastic Stem Cells

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 27184417
DOI: 10.1038/nrclinonc.2016.66
PMCID: PMC5461122

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.PMID 27184417Read ↗

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read ↗

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesSemantic proximity Read ↗

Update on triple‐negative breast cancers – highlighting subtyping update and treatment implicationSemantic proximity Read ↗

Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment optionsSemantic proximity Read ↗

New Biomarkers and Treatment Advances in Triple-Negative Breast CancerSemantic proximity Read ↗

Triple-negative breast cancer and the need for new therapeutic targets.Semantic proximity Read ↗

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Pathogenesis of Triple-Negative Breast CancerSemantic proximity Read ↗

Biology and Management of Patients With Triple-Negative Breast CancerSemantic proximity Read ↗

Triple-Negative Breast Cancer: Molecular Particularities Still a ChallengeSemantic proximity Read ↗

Divide and Conquer—Targeted Therapy for Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.